A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.
Authors
Sternberg, CHawkins, Robert E
Wagstaff, J
Salman, P
Mardiak, J
Barrios, C
Zarba, J
Gladkov, O
Lee, E
Szczylik, C
McCann, L
Rubin, S
Chen, M
Davis, I
Affiliation
Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy. Electronic address: cstern@mclink.it.Issue Date
2013-04
Metadata
Show full item recordAbstract
In this randomised phase III study (VEG105192; NCT00334282), pazopanib previously demonstrated statistically and clinically meaningful improvement of progression-free survival versus placebo in patients with advanced/metastatic renal cell carcinoma (mRCC). Final overall survival (OS) and updated safety results are now reported.Citation
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. 2013, 49 (6):1287-96 Eur J CancerJournal
European Journal of CancerDOI
10.1016/j.ejca.2012.12.010PubMed ID
23321547Type
ArticleLanguage
enISSN
1879-0852ae974a485f413a2113503eed53cd6c53
10.1016/j.ejca.2012.12.010
Scopus Count
Collections
Related articles
- An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma.
- Authors: Sternberg CN, Davis ID, Deen KC, Sigal E, Hawkins RE
- Issue date: 2014
- Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
- Authors: Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM
- Issue date: 2009 Jul 10
- First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial.
- Authors: Staehler M, Panic A, Goebell PJ, Merling M, Potthoff K, Herrmann E, de Geeter P, Vannier C, Hogrefe C, Marschner N, Grünwald V
- Issue date: 2021 Feb 15
- Pazopanib for the treatment of metastatic renal cell carcinoma.
- Authors: Pick AM, Nystrom KK
- Issue date: 2012 Mar
- Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
- Authors: Xie M, He CS, Huang JK, Lin QZ
- Issue date: 2015 Mar